Compass Therapeutics (CMPX) Cash from Investing Activities (2019 - 2026)

Compass Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at $38.4 million in Q1 2026.

• Quarterly Cash from Investing Activities rose 231.63% year-over-year to $38.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$66.5 million (down 206.41% YoY) and the FY2025 annual result came in at -$93.3 million, down 299.49% from the prior year.
• Cash from Investing Activities improved to $38.4 million in Q1 2026 per CMPX's latest filing, from -$3.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $38.4 million in Q1 2026 and troughed at -$105.5 million in Q2 2022.
• A 5-year average of -$7.8 million and a median of $1.2 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities slumped 17089.09% in 2022, then soared 2311.92% in 2023.
• Over 5 years, Cash from Investing Activities stood at -$46.6 million in 2022, then surged by 113.54% to $6.3 million in 2023, then jumped by 143.43% to $15.4 million in 2024, then slumped by 121.98% to -$3.4 million in 2025, then jumped by 1237.63% to $38.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $38.4 million, -$3.4 million, and -$95.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.